Injection of MM PBMC from patients with aggressive disease results in colonization of NOD SCID mice with human B and plasma cells
| Route of Injection . | Harvested Tissue . | Human Cells in Mouse Tissues (% of Total WBC) . | |
|---|---|---|---|
| B Lineage Cells . | |||
| Mean ± SE . | Range . | ||
| A. Intracardiac | Bone marrow (18) | 18 ± 6 | 0.3%-87% (9/18 mice) |
| Spleen (18) | 9 ± 1 | 2%-25% (13/18 mice) | |
| Peripheral Blood (11) | 6 ± 2 | 1%-14% (8/11 mice) | |
| B. Intraosseus | Bone marrow (6) | 48 ± 15 | 4%-86% (5/6 mice) |
| Spleen (6) | 15 ± 8 | 10%-23% (3/6 mice) | |
| Route of Injection . | Harvested Tissue . | Human Cells in Mouse Tissues (% of Total WBC) . | |
|---|---|---|---|
| B Lineage Cells . | |||
| Mean ± SE . | Range . | ||
| A. Intracardiac | Bone marrow (18) | 18 ± 6 | 0.3%-87% (9/18 mice) |
| Spleen (18) | 9 ± 1 | 2%-25% (13/18 mice) | |
| Peripheral Blood (11) | 6 ± 2 | 1%-14% (8/11 mice) | |
| B. Intraosseus | Bone marrow (6) | 48 ± 15 | 4%-86% (5/6 mice) |
| Spleen (6) | 15 ± 8 | 10%-23% (3/6 mice) | |
Mice were injected with unfractionated peripheral MM cells from patients 1, 2, and 5 with aggressive disease. For all 3 sets of mice, some of the mice were phenotypically positive for human B lineage cells (see Table 2).
Phenotypic analysis was performed on total white blood cells (WBC) after treatment with Intraprep to remove red blood cells. For all mice, bone marrow was harvested from the femur. WBC were stained with mAb to human CD45, CD19, and CD38. B lineage cells were defined as CD19+45+ and/or CD38hi45−/lo cells. Mouse cells were identified using antimurine CD45. Human CD45, CD19, CD38 mAb binding was absent from cells of uninjected NOD SCID control mice. Values are mean ± SE for those mice having phenotypically detectable cells.